Navigation Links
Colon cancer screening technique shows continued promise in new study
Date:6/9/2009

Recent clinical trials show that a new colon cancer screening technique created by Northwestern University researchers has a high enough sensitivity that it could potentially be as or more successful than a colonoscopy in screening for colon cancer.

The technique uses optical technology, called low-coherence enhanced backscattering (LEBS) spectroscopy, to analyze tissue samples taken from the base of the rectum. Light shines on the tissue, scatters, and some of that light bounces back to sensors in the probe. A computer analyzes the pattern of light scattering, looking for the "fingerprint" of carcinogenesis in the nanoarchitecture of the cells.

Researchers led by Vadim Backman, professor of biomedical engineering at the McCormick School of Engineering and Applied Science, obtained biopsies from patients undergoing colonoscopies and found that LEBS could detect the presence of growths elsewhere in the colon even though it just analyzed tissue from the base of the rectum.

The results were recently published in the journal Cancer Research. Clinical trials have been conducted in collaboration with Hemant Roy, M.D., director of gastroenterology research at NorthShore University HealthSystem.

The study is a step toward clinical application of the technology, since it used tissue samples near the location where doctors may ultimately use a probe to test technology.

"If you have a precancerous lesion in one part of the colon," said Backman, "even tissue that looks normal and is located far from the lesion or polyp will have molecular and other kinds of changes. It's the biological phenomenon called the 'field effect.' No one can detect these changes earlier than we can."

The study examined tissue from 219 patients. Results showed that for advanced polyps, the test had a sensitivity of 100 percent, which means that 100 percent of patients who had polyps were correctly identified as having them.

The larger number of patients in the more recent study allowed researchers to calculate the "area under the receiver operator characteristic" (AUROC), which is an analysis of the accuracy of the test in distinguishing healthy samples from diseased samples. While the sensitivity and specificity of tests may vary based on the threshold set by researchers for diagnosis, the AUROC measures the overall efficacy of the diagnostic technique. The analysis showed an 89.5 percent AUROC for the technique. (Clinically sound tests typically have an AUROC greater than 70 percent.)

The study provides a proof of concept that this sort of analysis could be a minimally intrusive colon cancer screening technique. Further studies with a compatible fiber optic probe are under way for multicenter clinical validation.

The work builds on previous success in using a suite of optical technologies to detect both colon and pancreatic cancer.


'/>"/>

Contact: Kyle Delaney
k-delaney@northwestern.edu
847-467-4010
Northwestern University
Source:Eurekalert

Related biology news :

1. Western diet linked to increased risk of colon cancer recurrence
2. Pig study sheds new light on the colonisation of Europe by early farmers
3. Analysis of breast and colon cancer genes finds many areas of differences between tumors
4. Genome update defines landscape of breast and colon cancers
5. $2.7 million awarded for metastatic colon cancer research
6. Colony collapse disorder symposium added to ESA Annual Meeting
7. DNA methylation shown to promote development of colon tumors
8. Vitamin D and calcium influence cell death in the colon, researchers find
9. Novel therapeutic strategy for colon cancer treatment
10. NCI grant launches clinical trials for colon cancer screening
11. Early stage colon cancer characterized by inactivation of gatekeeper gene
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/12/2017)...  Trovagene, Inc. (NASDAQ: TROV ), a ... that it has signed agreements with seven strategic partners ... Middle East for commercialization of the ... wave of international distribution agreements for Trovagene,s CLIA based ... The initial partners will introduce Trovagene,s liquid biopsy ...
(Date:1/11/2017)... -- Michael Johnson, co-founder of Visikol Inc. a company originally funded with ... to the elite "Forbes 30 Under 30" list in the Science ... 20 fields nationwide to be recognized as a leader in business ... ... a PhD candidate at Rutgers University. Visikol ...
(Date:1/4/2017)... thousands of attendees at this year,s International Consumer Electronics Show (CES), ... devices and services, will be featuring its new line of ULTRA CONNECT ... special CES Exhibit Suite , the new upper arm and wrist smart ... product platform.  Continue Reading ... ...
Breaking Biology News(10 mins):
(Date:1/11/2017)... ... ... Back pain relief technology is now available without a prescription at What ... relief for WAR members. , This spinal restoration platform boasts utilization of technology that ... suffering from chronic back pain. , What A Relief Back Pain Centers ...
(Date:1/11/2017)... , PITTSBURGH and BENGALURU, ... (NASDAQ, TASE: MYL) and Biocon Ltd. (BSE code: 532523, ... Drug Administration (FDA) has accepted Mylan,s biologics license application ... through the 351(k) pathway. This product is a proposed ... certain HER2-positive breast cancers. The anticipated FDA goal date ...
(Date:1/11/2017)... , Jan. 11, 2017  GenVec, Inc. ... delivery company, announced today that its chief scientific ... a talk entitled  "AdenoVerse™ platform for translational development ... Biotech Showcase at the upcoming Phacilitate Cell & ... Miami , Florida.  Dr. Brough,s presentation will ...
(Date:1/11/2017)... (PRWEB) , ... January 11, 2017 , ... ... signed a multi-year license agreement with Poseida Therapeutics Inc, the San Diego based ... genetic data. Poseida Therapeutics selected KBioBox in order to harness KBioBox’s powerful BioEngine ...
Breaking Biology Technology: